Metabolic origins of hyperoxaluria: the critical role of precursors and vitamin B6 status in rats Authors: Yoshihide Ogawa Published: 2026 ABSTRACT For decades, the clinical management of urolithiasis has emphasized dietary oxalate restriction. However, this review synthesizes over 40 years of research demonstrating that endogenous production, driven by specific metabolic precursors, plays the dominant role in oxalogenesis. Utilizing acute and chronic rat models, we quantified the conversion of glyoxylate, glycolate, ethylene glycol, hydroxypyruvate, and hydroxyproline into urinary oxalate. These studies establish a clear hierarchy of lithogenicity, with glyoxylate and glycolate emerging as the most potent precursors. Importantly, we identify Vitamin B6 (pyridoxine) deficiency as a critical metabolic “gatekeeper” that markedly amplifies oxalate synthesis. Deficiency states were found to increase precursor-to-oxalate conversion rates by up to 25-fold by suppressing hepatic alanine-glyoxylate aminotransferase (AGT) activity. Collectively, these findings support a paradigm shift in stone prevention: moving beyond dietary oxalate restriction toward managing precursor load and optimizing Vitamin B6 status. Introduction: the precursor paradigm Historically, calcium oxalate stone formation has been attributed largely to the direct ingestion of oxalate-rich foods. However, metabolic studies indicate that dietary oxalate contributes only 10–50% of urinary oxalate excretion [1, 2], with the remainder derived from endogenous metabolic pathways. The concept of “oxalate precursors” has evolved over several decades. The association between ethylene glycol toxicity and systemic oxalosis was first reported in 1939 by Stanbury et al. Subsequently, Hodgkinson and Williams classified metabolic intermediates such as glyoxylate and glycolate as key precursors, while Baker et al. identified ascorbate as a major endogenous contributor. Drug-induced hyperoxaluria has also been documented with agents including methoxyflurane, high-dose vitamin C, and xylitol infusion, underscoring the metabolic risks associated with specific chemical exposures [3]. We previously proposed that oxalate precursors are the primary drivers of hyperoxaluria [4, 5]. In contrast to direct oxalate ingestion, which is limited by intestinal absorption (approximately 5–15%) [6–11], precursors such as glycolate and glyoxylate are efficiently converted to oxalate by hepatic metabolism [Figure 1]. Fig. 1Metabolic Pathways of Urinary Oxalate Production in Normal Individuals. This schematic illustrates the baseline pathways contributing to the total daily urinary oxalate excretion (typically 20–40 mg) in a standard physiological state. The diagram highlights the dual origins of oxalate: Exogenous Contribution: Dietary oxalate typically contributes 10–20 mg per day, representing approximately 10–15% of total excretion under normal conditions. Endogenous Contribution: The majority of urinary oxalate is derived from the hepatic metabolism of the following precursors: Hydroxyproline (0–30 mg): Derived primarily from collagen catabolism. Ascorbate (0–15 mg): A steady contributor via slow non-enzymatic or enzymatic pathways. Xylitol (0–50 mg): A metabolic intermediate with variable contribution depending on dietary and metabolic flux. Glycolate/Glyoxylate (1–4 mg): Although their steady-state contribution is low, these are the most direct and potent metabolic intermediates in the oxalogenic pathway. Serine/Hydroxypyruvate: Non-essential but contributing pathways to the central glyoxylate pool. The values indicated represent estimated daily contributions to the total urinary oxalate pool. In healthy individuals, the Alanine-Glyoxylate Aminotransferase (AGT) pathway acts as a “safety valve,” transaminating glyoxylate to glycine and preventing excessive oxalate accumulation Metabolic Pathways of Urinary Oxalate Production in Normal Individuals. This schematic illustrates the baseline pathways contributing to the total daily urinary oxalate excretion (typically 20–40 mg) in a standard physiological state. The diagram highlights the dual origins of oxalate: Exogenous Contribution: Dietary oxalate typically contributes 10–20 mg per day, representing approximately 10–15% of total excretion under normal conditions. Endogenous Contribution: The majority of urinary oxalate is derived from the hepatic metabolism of the following precursors: Hydroxyproline (0–30 mg): Derived primarily from collagen catabolism. Ascorbate (0–15 mg): A steady contributor via slow non-enzymatic or enzymatic pathways. Xylitol (0–50 mg): A metabolic intermediate with variable contribution depending on dietary and metabolic flux. Glycolate/Glyoxylate (1–4 mg): Although their steady-state contribution is low, these are the most direct and potent metabolic intermediates in the oxalogenic pathway. Serine/Hydroxypyruvate: Non-essential but contributing pathways to the central glyoxylate pool. The values indicated represent estimated daily contributions to the total urinary oxalate pool. In healthy individuals, the Alanine-Glyoxylate Aminotransferase (AGT) pathway acts as a “safety valve,” transaminating glyoxylate to glycine and preventing excessive oxalate accumulation To further validate this paradigm, we employed rat models of calcium oxalate nephrolithiasis [12–20]. Although ethylene glycol and ammonium chloride are commonly used to induce experimental stone formation, our research focused on quantifying the specific conversion rates of multiple metabolic precursors. These studies establish a hierarchy of lithogenicity and identify Vitamin B6 (pyridoxine) deficiency as a metabolic “gatekeeper” that markedly amplifies oxalate synthesis. Materials and methods: experimental synthesis To quantify the lithogenic potential of various metabolic precursors, we synthesized data from a series of experiments conducted in our laboratory using male Wistar rats (approximately 180–200 g). In these studies, animals were acclimatized and randomized into paired groups (n = 6 per group) [13–20]. One group received a standard diet (Control, CE-2; NihonCLEA, Osaka), while the paired group was fed a Vitamin B6-deficient diet. Both groups were maintained for 3 weeks with free access to water. After the feeding period, rats were anesthetized (urethane 1.2 g/kg) and hydrated via the femoral vein with physiological saline (2.5–3.5 ml/h). Each group was then administered one of ten test substances by slow intravenous infusion over 10 min: glyoxylate (2 mg), glycolate (10 mg), ethylene glycol (20 mg), hydroxypyruvate (100 mg), hydroxyproline (100 mg), xylitol (200 mg), glycine (100 mg), glucose (200 mg), sorbitol (200 mg), or ascorbate (100 mg). Urine samples were collected by bladder puncture at hourly intervals for 5 h following infusion. Urine volume, oxalate excretion, and glycolate recovery were measured for each time point. Results Effect of Vitamin B6 Deficiency on Oxalate Recovery Vitamin B6 deficiency produced a marked increase in the conversion of several metabolic precursors into urinary oxalate compared with control rats (Table 1). Table 1Oxalogenesis from metabolic precursors in normal and Vitamin B6-deficient rats. Comparison of oxalate and glycolate recovery rates (%) following intravenous administration of various precursorsSubstance (Given Dose)Oxalate Recovery (%)Glycolate Recovery (%)NL / Vit B6 DefNL / Vit B6 Def Primary Precursors Glyoxylate (2 mg)8.44 / 25.142.70 / 1.44Glycolate (10 mg)2.03 / 14.403.60 / 12.53Ethylene Glycol (20 mg)0.28 / 7.150.66 / 7.22 Secondary Precursors Hydroxypyruvate (100 mg)0.68 / 2.420.53 / 0.76Hydroxyproline (100 mg)0.27 / 2.010.32 / 0.00 Non-Precursors / Sugars Xylitol (200 mg)0.00 / 0.450.07 / 0.28Glycine (100 mg)0.00 / 0.040.01 / 0.02Glucose (200 mg)0.00 / 0.000.00 / 0.00Sorbitol (200 mg)0.00 / 0.000.00 / 0.00Ascorbate (100 mg)0.00 / 0.000.0 0.00NL: Normal Control Group. Vit B6 Def: Vitamin B6-Deficient Group. Values represent the percentage of the administered dose recovered in urine as oxalate or glycolate over 5 h Table 1Oxalogenesis from metabolic precursors in normal and Vitamin B6-deficient rats. Comparison of oxalate and glycolate recovery rates (%) following intravenous administration of various precursorsSubstance (Given Dose)Oxalate Recovery (%)Glycolate Recovery (%)NL / Vit B6 DefNL / Vit B6 Def Primary Precursors Glyoxylate (2 mg)8.44 / 25.142.70 / 1.44Glycolate (10 mg)2.03 / 14.403.60 / 12.53Ethylene Glycol (20 mg)0.28 / 7.150.66 / 7.22 Secondary Precursors Hydroxypyruvate (100 mg)0.68 / 2.420.53 / 0.76Hydroxyproline (100 mg)0.27 / 2.010.32 / 0.00 Non-Precursors / Sugars Xylitol (200 mg)0.00 / 0.450.07 / 0.28Glycine (100 mg)0.00 / 0.040.01 / 0.02Glucose (200 mg)0.00 / 0.000.00 / 0.00Sorbitol (200 mg)0.00 / 0.000.00 / 0.00Ascorbate (100 mg)0.00 / 0.000.0 0.00NL: Normal Control Group. Vit B6 Def: Vitamin B6-Deficient Group. Values represent the percentage of the administered dose recovered in urine as oxalate or glycolate over 5 h Oxalogenesis from metabolic precursors in normal and Vitamin B6-deficient rats. Comparison of oxalate and glycolate recovery rates (%) following intravenous administration of various precursors NL: Normal Control Group. Vit B6 Def: Vitamin B6-Deficient Group. Values represent the percentage of the administered dose recovered in urine as oxalate or glycolate over 5 h Glyoxylate and Glycolate Glyoxylate was the most potent precursor. In control rats, 8.44% of the administered glyoxylate dose was recovered as oxalate; this increased roughly three-fold to 25.14% in Vitamin B6-deficient rats. Similarly, oxalate recovery from glycolate rose from 2.03% (control) to 14.40% (deficient).Ethylene Glycol The most dramatic relative increase was observed with ethylene glycol. Only 0.28% of the administered dose was recovered as oxalate in control rats, whereas this increased to 7.15% in Vitamin B6-deficient rats—representing a more than 25-fold enhancement.Secondary Precursors Hydroxypyruvate and hydroxyproline produced moderate oxalate formation. Vitamin B6 deficiency increased oxalate recovery from hydroxypyruvate (0.68% to 2.42%) and hydroxyproline (0.27% to 2.01%).Non-Precursors Xylitol, glycine, glucose, sorbitol, and ascorbate yielded negligible or undetectable oxalate recovery in this acute intravenous model, regardless of Vitamin B6 status. Glyoxylate and Glycolate Glyoxylate was the most potent precursor. In control rats, 8.44% of the administered glyoxylate dose was recovered as oxalate; this increased roughly three-fold to 25.14% in Vitamin B6-deficient rats. Similarly, oxalate recovery from glycolate rose from 2.03% (control) to 14.40% (deficient). Glyoxylate and Glycolate Glyoxylate was the most potent precursor. In control rats, 8.44% of the administered glyoxylate dose was recovered as oxalate; this increased roughly three-fold to 25.14% in Vitamin B6-deficient rats. Similarly, oxalate recovery from glycolate rose from 2.03% (control) to 14.40% (deficient). Ethylene Glycol The most dramatic relative increase was observed with ethylene glycol. Only 0.28% of the administered dose was recovered as oxalate in control rats, whereas this increased to 7.15% in Vitamin B6-deficient rats—representing a more than 25-fold enhancement. Ethylene Glycol The most dramatic relative increase was observed with ethylene glycol. Only 0.28% of the administered dose was recovered as oxalate in control rats, whereas this increased to 7.15% in Vitamin B6-deficient rats—representing a more than 25-fold enhancement. Secondary Precursors Hydroxypyruvate and hydroxyproline produced moderate oxalate formation. Vitamin B6 deficiency increased oxalate recovery from hydroxypyruvate (0.68% to 2.42%) and hydroxyproline (0.27% to 2.01%). Secondary Precursors Hydroxypyruvate and hydroxyproline produced moderate oxalate formation. Vitamin B6 deficiency increased oxalate recovery from hydroxypyruvate (0.68% to 2.42%) and hydroxyproline (0.27% to 2.01%). Non-Precursors Xylitol, glycine, glucose, sorbitol, and ascorbate yielded negligible or undetectable oxalate recovery in this acute intravenous model, regardless of Vitamin B6 status. Non-Precursors Xylitol, glycine, glucose, sorbitol, and ascorbate yielded negligible or undetectable oxalate recovery in this acute intravenous model, regardless of Vitamin B6 status. Glycolate Recovery Trends Glycolate excretion patterns indicated a metabolic shift. Recovery of glycolate following glyoxylate administration was lower in Vitamin B6-deficient rats (1.44%) compared with controls (2.70%). This suggests that, in the absence of adequate Vitamin B6, glyoxylate metabolism is diverted away from detoxification pathways (e.g., conversion to glycine) and toward oxalate synthesis. Discussion The Metabolic Mechanism: The “AGT Checkpoint” The marked hyperoxaluria observed in Vitamin B6-deficient rats is primarily attributable to impaired alanine: glyoxylate aminotransferase (AGT) activity [21]. Under physiological conditions, AGT requires pyridoxal-5’-phosphate (active Vitamin B6) as an essential cofactor to transaminate glyoxylate into glycine—a safe metabolic endpoint. In the setting of Vitamin B6 deficiency, this conversion is markedly inhibited (Fig. 2). As a result, accumulated glyoxylate is diverted toward alternative oxidative pathways, where it is irreversibly converted to oxalate by lactate dehydrogenase (LDH) or glycolate oxidase (GO). This “metabolic traffic jam” explains the 25-fold increase in oxalate production from ethylene glycol and the substantial rise in glyoxylate-derived oxalate.\. Fig. 2Metabolic diversion of glyoxylate in Vitamin B6 deficiency. Schematic representation of glyoxylate metabolism highlighting the critical role of Vitamin B6. (A) Under physiological conditions, alanine: glyoxylate aminotransferase (AGT) utilizes pyridoxal-5’-phosphate (PLP; active Vitamin B6) as an essential cofactor to transaminate glyoxylate into glycine, thereby detoxifying it. (B) In Vitamin B6 deficiency, AGT activity is impaired (red “X”), preventing conversion to glycine. Accumulated glyoxylate is consequently diverted toward oxidative pathways, where it is irreversibly converted to oxalate by lactate dehydrogenase (LDH) and glycolate oxidase (GO) Metabolic diversion of glyoxylate in Vitamin B6 deficiency. Schematic representation of glyoxylate metabolism highlighting the critical role of Vitamin B6. (A) Under physiological conditions, alanine: glyoxylate aminotransferase (AGT) utilizes pyridoxal-5’-phosphate (PLP; active Vitamin B6) as an essential cofactor to transaminate glyoxylate into glycine, thereby detoxifying it. (B) In Vitamin B6 deficiency, AGT activity is impaired (red “X”), preventing conversion to glycine. Accumulated glyoxylate is consequently diverted toward oxidative pathways, where it is irreversibly converted to oxalate by lactate dehydrogenase (LDH) and glycolate oxidase (GO) Glycolate and Glyoxylate Metabolism Glycolate, derived from phosphoglycolate in plants or endogenous metabolism, is rapidly oxidized to glyoxylate in hepatocyte peroxisomes. Once formed, glyoxylate becomes the central metabolic pivot. It may be reduced back to glycolate or transaminated to glycine via peroxisomal AGT and reduction by cytosolic GRHPR; alternatively, it may be oxidized to oxalate via LDH. The lower glycolate recovery in Vitamin B6-deficient rats (1.44% vs. 2.70%) is due to substrate competition. Because the AGT pathway is blocked, glyoxylate is consumed so rapidly by the LDH/GO pathways that less is available for reduction back to glycolate. Our findings confirm that in the absence of adequate Vitamin B6, the AGT “safety valve” fails, and the LDH pathway predominates. This mechanism parallels clinical observations in which pyridoxilate—a compound combining pyridoxine and glyoxylate—paradoxically induced stone formation, likely because the exogenous glyoxylate load exceeded the metabolic capacity [22]. Translational Perspectives: Rat Models vs. Human Metabolism Recent systematic reviews in humans and advanced genetic rat models further support the critical role of AGT activity in managing the endogenous oxalate precursor load. The systematic review by Dick et al. (2026) suggests that dietary oxalate contributes approximately 10–50% of total urinary excretion in humans, which aligns with our rat data demonstrating that endogenous oxalogenesis is the dominant factor when precursor loads are high [23]. Furthermore, the AGT-knockout model developed by Li et al. (2021) allows for a meaningful contrast between the absolute AGT deficiency seen in Primary Hyperoxaluria Type 1 (PH1) and the dietary-induced Vitamin B6 deficiency investigated in this study [24]. Our findings clarify that Vitamin B6 deficiency creates a “functional” phenocopy of PH1; while the AGT protein may be present, the lack of its essential cofactor leads to a metabolic diversion toward oxalate synthesis that mimics the genetic disease state. Ascorbate and Sugars The contribution of ascorbate to urinary oxalate remains controversial. Although some reports suggest that ascorbate may account for 30–50% of urinary oxalate [25], our acute IV loading study detected no measurable conversion. This suggests that ascorbate-to-oxalate conversion may be a slow, non-enzymatic process not captured in a 5-hour sampling window, or that its contribution is overestimated in non-alkaline environments [26]. Similarly, sugars such as xylitol and sorbitol produced negligible oxalate in this acute model, contradicting earlier concerns regarding xylitol infusion-induced hyperoxaluria [3]. The Context of Dietary Oxalate Although this review emphasizes metabolic origins, dietary oxalate remains a contributing factor. High oxalate concentrations are found in spinach, rhubarb, tea, and cocoa, and oxalate-rich foods often contain multiple oxalate precursors [27]. Nevertheless, in individuals consuming a balanced diet, only 10–15% of urinary oxalate originates from dietary intake [2]. Absorption is influenced by dietary calcium and magnesium and the presence of Oxalobacter formigenes. Importantly, our findings demonstrate that even with low dietary oxalate intake, a metabolic defect such as Vitamin B6 deficiency—combined with precursor exposure (e.g., gelatin/hydroxyproline or food additives)—can generate substantial endogenous oxalate loads. Conclusion Hyperoxaluria arises from multiple etiologies, yet the role of metabolic precursors is frequently underestimated. Our findings demonstrate that Vitamin B6 deficiency acts as a critical metabolic multiplier, converting otherwise benign precursors into substantial oxalate loads through the failure of the AGT pathway. While these results in rat models provide a clear mechanical proof-of-concept for “functional” AGT deficiency, further clinical studies are needed to quantify these conversion rates in humans. Nevertheless, effective clinical prevention strategies should expand beyond traditional dietary oxalate restriction to include the management of precursor exposure and the optimization of Vitamin B6 status.